Impact of FDG-PET/CT in the management of lymphoma

Shingo Baba, Koichiro Abe, Takuro Isoda, Yasuhiro Maruoka, Masayuki Sasaki, Hiroshi Honda

Research output: Contribution to journalReview article

27 Citations (Scopus)

Abstract

Since the introduction of 67Gallium-citrate 30 years ago, nuclear medicine has played an important role in the evaluation of malignant lymphoma. During that time, several radiotracers were evaluated as potential alternatives for the diagnosis of lymphoma, but the introduction of 18F-fluorodeoxyglucose PET (FDG-PET) marked a major turning point. FDG-PET took over most of the role of gallium, and is now an essential tool in the diagnosis of lymphoma. FDG-PET is increasingly being used for assessment of the tumor staging prior to treatment, for evaluating the response to treatment, and for monitoring the early reactions to therapy to predict the final outcome. FDG-PET has been shown to have more accurate diagnostic capability than conventional CT and MRI for distinguishing the tumor necrosis and residual masses frequently seen after therapy in lymphoma patients without any clinical and biochemical manifestation. Malignant lymphoma is the first disease for which FDG-PET was adopted as a tool for response assessment in the international standard criteria. However, lymphoma does not always display a clear high uptake, and there are some pitfalls in assessing the response to therapy. This review will highlight the most important applications of FDG-PET in lymphoma, focusing on the advantages and pitfalls of this imaging, and past and ongoing efforts to standardize the use of FDG-PET, particularly in response to assessment and therapy monitoring.

Original languageEnglish
Pages (from-to)701-716
Number of pages16
JournalAnnals of Nuclear Medicine
Volume25
Issue number10
DOIs
Publication statusPublished - Dec 1 2011

Fingerprint

Lymphoma
Therapeutics
Gallium
Neoplasm Staging
Nuclear Medicine
Fluorodeoxyglucose F18
Residual Neoplasm
Citric Acid
Necrosis

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

Cite this

Impact of FDG-PET/CT in the management of lymphoma. / Baba, Shingo; Abe, Koichiro; Isoda, Takuro; Maruoka, Yasuhiro; Sasaki, Masayuki; Honda, Hiroshi.

In: Annals of Nuclear Medicine, Vol. 25, No. 10, 01.12.2011, p. 701-716.

Research output: Contribution to journalReview article

Baba, Shingo ; Abe, Koichiro ; Isoda, Takuro ; Maruoka, Yasuhiro ; Sasaki, Masayuki ; Honda, Hiroshi. / Impact of FDG-PET/CT in the management of lymphoma. In: Annals of Nuclear Medicine. 2011 ; Vol. 25, No. 10. pp. 701-716.
@article{f1d5fc15c0874327a623be839c908369,
title = "Impact of FDG-PET/CT in the management of lymphoma",
abstract = "Since the introduction of 67Gallium-citrate 30 years ago, nuclear medicine has played an important role in the evaluation of malignant lymphoma. During that time, several radiotracers were evaluated as potential alternatives for the diagnosis of lymphoma, but the introduction of 18F-fluorodeoxyglucose PET (FDG-PET) marked a major turning point. FDG-PET took over most of the role of gallium, and is now an essential tool in the diagnosis of lymphoma. FDG-PET is increasingly being used for assessment of the tumor staging prior to treatment, for evaluating the response to treatment, and for monitoring the early reactions to therapy to predict the final outcome. FDG-PET has been shown to have more accurate diagnostic capability than conventional CT and MRI for distinguishing the tumor necrosis and residual masses frequently seen after therapy in lymphoma patients without any clinical and biochemical manifestation. Malignant lymphoma is the first disease for which FDG-PET was adopted as a tool for response assessment in the international standard criteria. However, lymphoma does not always display a clear high uptake, and there are some pitfalls in assessing the response to therapy. This review will highlight the most important applications of FDG-PET in lymphoma, focusing on the advantages and pitfalls of this imaging, and past and ongoing efforts to standardize the use of FDG-PET, particularly in response to assessment and therapy monitoring.",
author = "Shingo Baba and Koichiro Abe and Takuro Isoda and Yasuhiro Maruoka and Masayuki Sasaki and Hiroshi Honda",
year = "2011",
month = "12",
day = "1",
doi = "10.1007/s12149-011-0549-0",
language = "English",
volume = "25",
pages = "701--716",
journal = "Annals of Nuclear Medicine",
issn = "0914-7187",
publisher = "Springer Japan",
number = "10",

}

TY - JOUR

T1 - Impact of FDG-PET/CT in the management of lymphoma

AU - Baba, Shingo

AU - Abe, Koichiro

AU - Isoda, Takuro

AU - Maruoka, Yasuhiro

AU - Sasaki, Masayuki

AU - Honda, Hiroshi

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Since the introduction of 67Gallium-citrate 30 years ago, nuclear medicine has played an important role in the evaluation of malignant lymphoma. During that time, several radiotracers were evaluated as potential alternatives for the diagnosis of lymphoma, but the introduction of 18F-fluorodeoxyglucose PET (FDG-PET) marked a major turning point. FDG-PET took over most of the role of gallium, and is now an essential tool in the diagnosis of lymphoma. FDG-PET is increasingly being used for assessment of the tumor staging prior to treatment, for evaluating the response to treatment, and for monitoring the early reactions to therapy to predict the final outcome. FDG-PET has been shown to have more accurate diagnostic capability than conventional CT and MRI for distinguishing the tumor necrosis and residual masses frequently seen after therapy in lymphoma patients without any clinical and biochemical manifestation. Malignant lymphoma is the first disease for which FDG-PET was adopted as a tool for response assessment in the international standard criteria. However, lymphoma does not always display a clear high uptake, and there are some pitfalls in assessing the response to therapy. This review will highlight the most important applications of FDG-PET in lymphoma, focusing on the advantages and pitfalls of this imaging, and past and ongoing efforts to standardize the use of FDG-PET, particularly in response to assessment and therapy monitoring.

AB - Since the introduction of 67Gallium-citrate 30 years ago, nuclear medicine has played an important role in the evaluation of malignant lymphoma. During that time, several radiotracers were evaluated as potential alternatives for the diagnosis of lymphoma, but the introduction of 18F-fluorodeoxyglucose PET (FDG-PET) marked a major turning point. FDG-PET took over most of the role of gallium, and is now an essential tool in the diagnosis of lymphoma. FDG-PET is increasingly being used for assessment of the tumor staging prior to treatment, for evaluating the response to treatment, and for monitoring the early reactions to therapy to predict the final outcome. FDG-PET has been shown to have more accurate diagnostic capability than conventional CT and MRI for distinguishing the tumor necrosis and residual masses frequently seen after therapy in lymphoma patients without any clinical and biochemical manifestation. Malignant lymphoma is the first disease for which FDG-PET was adopted as a tool for response assessment in the international standard criteria. However, lymphoma does not always display a clear high uptake, and there are some pitfalls in assessing the response to therapy. This review will highlight the most important applications of FDG-PET in lymphoma, focusing on the advantages and pitfalls of this imaging, and past and ongoing efforts to standardize the use of FDG-PET, particularly in response to assessment and therapy monitoring.

UR - http://www.scopus.com/inward/record.url?scp=83855162784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83855162784&partnerID=8YFLogxK

U2 - 10.1007/s12149-011-0549-0

DO - 10.1007/s12149-011-0549-0

M3 - Review article

C2 - 22037934

AN - SCOPUS:83855162784

VL - 25

SP - 701

EP - 716

JO - Annals of Nuclear Medicine

JF - Annals of Nuclear Medicine

SN - 0914-7187

IS - 10

ER -